The worldwide Idiopathic Thrombocytopenic Purpura Therapeutics Market is
projected to attain nearly USD 566 million by 2020. It can expand at a 5.9 %
CAGR over the forecast period (2014-2020). The market stood at around USD 382
million in 2013. It is driven by favorable government policies such as the U.S.
Orphan Drug Act. Demand of combination therapies like dexamethasone and TPO-RA
is another factor which may influence market growth.
ITP (idiopathic thrombocytopenic purpura) is a rare
disease with low affliction rates. This disease leads to excessive bruising or
bleeding due to the lack of blood platelets. It is also known as immune
thrombocytopenia and can affect children and adults alike. ITP affects nearly
0.3% out of every 100,000 in the U.S. Commercialization of new drugs like
IVIG3I 10% and Avatrombopag is anticipated to propel demand over the forecast
period.
Browse Details of Report @ https://www.hexaresearch.com/research-report/idiopathic-thrombocytopenic-purpura-itp-therapeutics-industry
The global Idiopathic Thrombocytopenic Purpura
Therapeutics Market is segmented according to products and regions. As per
products, the classifications are TPO-RA (thrombopoetin receptor agonist),
anti-D immunoglobulin, intravenous immunoglobulin (IVIG), anti-D
immunoglobulins, corticosteroids, and others. Corticosteroids were valued over
USD 125 million in 2013 and are the most widely preferred drug for treating
ITP. Its high share in overall revenues can be attributed to its low price.
TPO-RA can experience surging demand on account of commercialization of
Avatrombopag. This can be attributed to the use of TPO-RA in splenectomized
patients suffering relapses. Avatrombopag can act as a second line of defense
due to its positive clinical trial results.
High response rates displayed by patients administered
with Eltrombopag and Romiplostim can positively impact the TPO-RA segment till
2020. Other therapeutic classes are interferon, immunosuppressant, and
monoclonal antibodies (mAbs). mAbs such as Rituximab were used frequently in
Europe till 2013. However, patent expiry of the same has created scope for drug
manufacturers to develop biosimilars.
North America, Europe, Asia Pacific, and RoW (Rest of the
World) are regional segments of the worldwide ITP market. North America led the
overall industry in 2013 owing to favorable government initiatives, rising ITP
cases, and high research funding. Clinical trials based on combination therapy
and drug developments are expected to spur regional demand over the forecast period.
North America had a revenue share exceeding 40% in 2013.
Europe was the second largest market in 2013 propelled by
high product penetration and favorable initiatives pertaining to its
production. Asia Pacific is expected to prosper considerably over the next 6
years due to the untapped markets in India and China. Furthermore,
sophisticated healthcare and government initiatives in Australia and Japan can
contribute significantly to regional demand.
Notable players of the Idiopathic Thrombocytopenic Purpura
Therapeutics Market are Grifols Biologicals Inc.; GlaxoSmithKline (GSK) Plc;
Amgen Inc.; and F. Hoffman-La Roche AG. These companies invest robustly in
research and development to launch newer products in order to sustain their
respective market shares.
GSK recently got approval for its trademark product
“Revolade™” by Health Canada, the department of the government of Canada that
looks into national public health. This product is a capsule which needs to be
taken orally to treat ITP. It can help boost production of blood platelets.
Amgen Inc.’s “Nplate” helps restore blood platelets in children. It can act as
a viable alternative to treat severe bleeding concurrent with ITP. This drug
had generated nearly USD 400 million in 2013. Although Promacta and Nplate
received approvals at the same time, the former is expected to dominate the
market in the near future.
Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry
No comments:
Post a Comment